Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available clinical trials

  • A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer


    Brage Garofalo, Director, Clinical Study Management (

    This is a study of EIK1001 in combination with pembrolizumab and chemotherapy in patients with Stage 4 squamous and nonsquamous non-small cell lung cancer who have not received either chemotherapy or immunotherapy. The purpose of this study is determine if EIK1001 works in combination with standard chemotherapy and pembrolizumab (immunotherapy).

    Who can participate?

    To be eligible, you must been diagnosed with non-small cell lung cancer (nonsquamous or squamous) and not have already received prior treatment for your lung cancer, including radiation within 6 months of your first treatment.

  • ALISCA-Lung1: A Phase 2 Study of Alisertib in Patients with Extensive Stage Small Lung Cancer


    ALISCA-Lung1 is a clinical trial that is exploring whether an investigational medication called alisertib is effective in treating patients with pathologically confirmed extensive-stage small-cell lung cancer following progression on or after first-line treatment with platinum-based chemotherapy and immunotherapy.

    Who can participate?

    Eligible patients must be at least 18 years old and cannot have used an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib in any setting. There are additional inclusion and exclusion criteria. The investigator at the study center will determine if you meet all of the criteria.

  • ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide)


    Marshika Vickers
    Phone Number: 510-473-2872

    ASTRIDE: A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    This is a study to learn the effects of the study drug plus chemotherapy on ES-SCLC, compared with atezolizumab combined with chemotherapy. Atezolizumab combined with chemotherapy (etoposide + carboplatin) was approved by the Food and Drug Administration (FDA) in March 2019 in the treatment of ES-SCLC.

    Who can participate?

    This study is for adults who:

    • Are 18 years of age and older
    • Have been diagnosed with ES-SCLC
    • Have NOT already received treatment for ES-SCLC
      Note: If you have received chemotherapy for limited-stage SCLC, it must have taken place more than 6 months before starting this study.

    Other criteria also apply.

  • Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation


    Sunhye Im (Kelly)
    Head of Clinical Operation Team
    TEL. + 82 (0)2-6006-7621
    FAX. +82 (0)2-866-7657

    ABN401 as a potential c-MET tyrosine kinase inhibitor to treat oncologic malignancies, Abion Inc would like to explore the Phase 2 clinical study (ABN401-003) to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 in specific populations of advance solid tumors with c-MET alterations, as monotherapy and in combination with standard treatment.

    Who can participate?

    Key Inclusion Criteria:

    • Must have histologically or cytologically confirmed NSCLC, advanced, recurrent, or metastatic.
    • MET exon 14 skipping suspected by local or central biomarker assessment.
    • Anti-tumor treatment naïve subject upon refusal to receive 1st line standard of care, or not tolerated to 1st line standard of care, or progressed after standard of care with no greater than 2 prior treatment regimens (neoadjuvant, adjuvant, and maintenance therapies do not qualify as separate treatment regimens).

    Key Exclusion Criteria:

    • Previous treatment with c-MET inhibitors or hepatocyte growth factor (HGF)-targeting therapy.